Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Expands By 120.7%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 3,746,865 shares, a growth of 120.7% from the June 30th total of 1,697,593 shares. Approximately 9.6% of the shares of the company are sold short. Based on an average daily trading volume, of 686,566 shares, the days-to-cover ratio is presently 5.5 days.

Coeptis Therapeutics Price Performance

Shares of ZSQR stock traded up $0.47 during trading hours on Wednesday, hitting $5.29. The company’s stock had a trading volume of 339,266 shares, compared to its average volume of 252,434. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. Coeptis Therapeutics has a twelve month low of $4.32 and a twelve month high of $21.41. The stock has a market cap of $272.06 million, a price-to-earnings ratio of -2.10 and a beta of -0.25. The business has a fifty day moving average of $9.69 and a 200-day moving average of $11.58.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Coeptis Therapeutics presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Coeptis Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new position in Coeptis Therapeutics in the 4th quarter valued at about $259,000. State Street Corp grew its stake in shares of Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after acquiring an additional 6,962 shares in the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the last quarter. Institutional investors and hedge funds own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.